Axcella health.

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. Axcella Health Inc. Common Stock (AXLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Axcella Health has an overall rating of 3.9 out of 5, based on over 27 reviews left anonymously by employees. 80% of employees would recommend working at Axcella Health to a friend and 65% have a positive outlook for the business. This rating has been stable over the past 12 months.On September 18, 2023, Axcella Health Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value of $0.001 per share (the “Common Stock”).

Funding. Axcella has raised a total of. $185.5M. in funding over 6 rounds. Their latest funding was raised on Oct 13, 2022 from a Post-IPO Equity round. Axcella is registered under the ticker NASDAQ:AXLA . Their stock opened with $20.00 in its May 8, 2019 IPO. Axcella is funded by 5 investors. Fidelity and Nestlé Health Science are the most ...

Researchers from the University of Oxford have reported findings from a Phase 2 clinical trial investigating the efficacy of an investigational treatment against long COVID fatigue.The study (reported in Lancet eClinical Medicine) found participants given the treatment, developed by US pharmaceutical company Axcella Therapeutics, reported …Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions.

C/O AXCELLA HEALTH INC. 840 MEMORIAL DRIVE (Street) CAMBRIDGE: MA: 02139 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Axcella Health Inc. [ AXLA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: 10% Owner: X: Officer (give title below)Axcella also to present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. CAMBRIDGE, Mass., Jan. 3, 2018 – Axcella Health, a biotechnology company pioneering Designed Amino Acid Compositions (DAAC™) as therapeutics across a range of important diseases, announced today that David R. …The Bountiful Company. The Bountiful Company is a pure-play leader in global nutrition, working at the intersection of science and nature. The brands we’ve acquired are: Nature’s Bounty, Puritan’s Pride, Solgar, Esther-C, Osteo Bi-Flex, and Sundown. Visit The Bountiful Company website. Read Related News Story.Long COVID Axcella Health Flagship Pioneering COVID-19. Behind the unrelenting challenges of long COVID, which leaves many of the disease’s sufferers with exhaustion, sleep problems and brain ...

Dec 1, 2023 · Axcella Health Inc + Add to watchlist AXLA:PKL Actions Price (USD) 3.20 Today's Change -1.38 / -30.13% Shares traded 42.80k 1 Year change -85.29% Beta 0.7876 Data delayed at least 15 minutes, as...

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

View the latest Axcella Health Inc. (AXLA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Dec 1, 2023 · Axcella Announces Reverse Stock Split Effective September 19, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using com... Disclosure statement. Roger Fielding consults for Merck, Pfizer, Eli Lilly, Axcella Health, Segterra, Amazentis, Nestle, Biophytis, Astellas, Juvicell, and Cytokinetic.Jun 30, 2021 · Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. About Axcella Health Axcella is designing and developing AXA Candidates, compositions of EMMs engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Our AXA Candidates are generated from our proprietary, human-focused AXA Development …Aug 29, 2023 · AXA1125 is a novel composition of EMMs designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. Axcella was previously granted patents related to ...

CAMBRIDGE, Mass., August 29, 2023--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach …Buying health insurance for the first time seems confusing at first. You are presented with so many insurance options that you are unsure which is best. In reality, getting your first health insurance plan does not have to be daunting.The following insiders have sold AXLA shares in the last 24 months: Margaret Koziel ($2,870.25), and William Hinshaw ($52,308.75). How much insider selling is happening at Axcella Health? Insiders have sold a total of 1,374 Axcella Health shares in the last 24 months for a total of $55,179.00 sold.In healthcare record; defined as the subject visiting a general practitioner for loss of appetite in the previous 12 months. 0.20%: Mortality: Cai et al.; 2020; ... Roger A. …Apr 15, 2023 · Axcella Health has an overall rating of 3.9 out of 5, based on over 27 reviews left anonymously by employees. 80% of employees would recommend working at Axcella Health to a friend and 65% have a positive outlook for the business. This rating has been stable over the past 12 months. Aug 2, 2022 · CHICAGO, Aug 2 (Reuters) - One of the first trials aimed at tackling long COVID helped some patients recover from lingering physical and mental fatigue, although the drug developed by Axcella...

tolerability, and biologic activity of AXA1125 and AXA1957 in NAFLD. METHODS: In this multicenter, 16-week, placebo-controlled, single-blind, randomized clinical study in subjects with NAFLD stratified by type 2 diabetes, AXA1125 24 g, AXA1957 13.5 g or 20.3 g, or placebo was administered twice daily. Key metabolism (MRI-proton density fat fraction [MRI-PDFF] and homeostasis model assessment ...

Axcella Health Inc. (AXLA) has been on a downward spiral lately with significant selling pressure. After declining 47.9% over the past four weeks, the stock looks well positioned for a trend ...Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The ...Earnings & Valuation. This table compares Axcella Health and Novozymes A/S’s gross revenue, earnings per share and valuation. Novozymes A/S has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Novozymes A/S, indicating that it is currently the more affordable of the two …Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957 10.07.2019; Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors 08.23.2019; Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study 07.31.2019; Next According to the issued ratings of 2 analysts in the last year, the consensus rating for Axcella Health stock is Hold based on the current 2 hold ratings for AXLA. The average twelve-month price prediction for Axcella Health is $50.00 with a high price target of $50.00 and a low price target of $50.00. Learn more on AXLA's analyst rating history.The for- therapies against K. pneumonia are critical for public health ward (5 -GGGGAATTCACAGCACAATCCCAGGTAT 0 0 [4, 27, 29]. Since DnaB is required for …AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) _____ Delaware: 001-38901 ...Axcella Health has a consensus price target of $50.00, suggesting a potential upside of 4,639.34%. Given Axcella Health’s higher possible upside, analysts plainly believe Axcella Health is more ...

He has served as founding CEO of over 10 companies including Seres, Evelo, and Axcella. David has been broadly recognized as a world-leading innovator: ... David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering, through the Health Sciences and Technology program completing the fastest dual degree in the …

AXA1125 is a novel composition of EMMs designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. Axcella was previously granted patents related to ...

Jan 6, 2022 · About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. Axcella Health Inc. 5.43 +0.01 +0.18%: TRENDING. 1. OpenAI's interim CEO pledges probe into Altman's exit, reform management. 2. UPDATE 1-Canada's First Quantum further slows operations at Panama ...What is Axcella Health's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Axcella Health stock is Hold based on the current 2 hold ratings for AXLA. The average twelve-month price prediction for Axcella Health is $50.00 with a high price target of $50.00 and a low price ...Axcella Health (NASDAQ: AXLA) stock should jump 2,500% at the open. AXLA stock is not going to rise 25x as a part of the unusual price movements we’ve been seeing this past few weeks - this is a purely nominal price change, one designed to solve a particular problem. That problem is how to maintain the Nasdaq listing in the face of a low ...Oct 29, 2023 · Axcella Health Inc. is a company that has been making waves in the field of therapeutic solutions. With their innovative approach, they have been able to develop groundbreaking treatments that have the potential to revolutionize the way we approach healthcare. One of the key aspects of Axcella Health Inc.’s approach is their focus on the ... Over the last year, we can see that insiders have bought 89.01k shares worth US$170k. On the other hand they divested 17.69k shares, for US$29k. Overall, Axcella Health insiders were net buyers ...Axcella Health Inc (NASDAQ: AXLA) is reportedly looking for funding to support its advanced trial of a drug initially found to improve fatigue in long Covid patients. An early-stage trial of the ...Axcella Health Inc. (AXLA) has been on a downward spiral lately with significant selling pressure. After declining 47.9% over the past four weeks, the stock looks well positioned for a trend ...

[email protected] +1 (888) 828-0618. Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission (SEC). Webull Financial LLC is a member of the Financial Industry Regulatory Authority ( FINRA ), Securities Investor Protection Corporation ( SIPC ...A health appraisal, or health risk assessment, is a tool that allows health providers to gather information about an individual’s physical health and lifestyle.Axcella Health Inc (NASDAQ: AXLA) announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and …Instagram:https://instagram. p v hvanguard dividend growth invnasdaq mucarter worth stock picks Axcella Health (NASDAQ:AXLA) is one of the top biotech stocks to avoid. The company continues to attempt to commercialize its proprietary combination of amino acids to treat long-term COVID-19 ... double eagle valueautomation trading Nov 1, 2022 · Axcella’s net loss for the quarter and nine months ended September 30, 2022, was $17.8 million, or $0.34 per basic and diluted share, and $58.2 million or $1.19 per share, respectively. Our net ... trading options apps Axcella Health Inc. (AXLA) has been on a downward spiral lately with significant selling pressure. After declining 47.9% over the past four weeks, the stock looks well positioned for a trend ...Axcella Health, Inc: ClinicalTrials.gov Identifier: NCT05152849 Other Study ID Numbers: AXA1125-201 : First Posted: December 10, 2021 Key Record Dates: Last Update Posted: October 20, 2022 Last Verified: November 2021